<DOC>
	<DOC>NCT00811460</DOC>
	<brief_summary>This crossover study will assess the effect of 2 doses of Taspoglutide on first- and second-phase insulin secretion in patients with type 2 diabetes. Patients will receive a continuous subcutaneous infusion of a)the Immediate Release Formulation (IRF)of Taspoglutide 300 micrograms/day for 2 days followed by Taspoglutide 800 micrograms/day for 2 days or b)saline placebo for 2+2 days. After a washout period of 10-15 days, patients will be crossed-over for further treatment;those receiving Taspoglutide in period 1 will receive placebo in period 2, and vice versa. On days 2 and 4 of each period, insulin secretion patterns will be assessed. The anticipated time on study treatment is &lt;3 months, and the target sample size is &lt;100 individuals.</brief_summary>
	<brief_title>A Study of Taspoglutide in Type 2 Diabetic Patients</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Glucagon-Like Peptide 1</mesh_term>
	<criteria>adult patients, 1865 years of age; type 2 diabetes mellitus; treated with diet and exercise alone, or in combination with stable metformin for at least 3 months prior to screening. type 1 diabetes mellitus; type 2 diabetes duration of &lt;3 months; treatment with any oral antihyperglycemic medication other than metformin monotherapy during last 3 months; treatment with insulin for &gt;7 days within 6 months prior to screening.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>